Massive deal to revitalize biotech

Israel’s Compugen (see here previously) only had six months’ cash left when it was rescued by Gilead Sciences in a deal worth up to $848 million. Gilead will license Compugen’s pre-clinical cancer antibody COM503 that frees up the peptide InterLeukin 18 (IL-18) to destroy tumors.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *